Related Experiment Video
Updated: Feb 25, 2026

High-throughput Antiviral Assays to Screen for Inhibitors of Zika Virus Replication
Published on: October 30, 2021
Doubled dosage of sofosbuvir is expected for inhibiting Zika virus infection
Somsri Wiwanitkit1, Viroj Wiwanitkit2
1Wiwanitkit House, Bangkhae, Bangkok Thailand.
Abstract:
Sofosbuvir is a new antiviral drug that has been recommended for management of hepatitis C virus (HCV) for a few years. New researches support that sofosbuvir might be useful for the management of Zika virus infection. Based on the pharmacological activity, inhibiting the HCV RNA-dependent RNA polymerase (RdRp or NS5 protein), sofosbuvir is proposed for its effectiveness against Zika virus infection. Here, the authors used a mathematical modelling theoretical approach to predict the expected dosage of sofosbuvir for inhibiting Zika virus infection. Based on the modeling study, if sofosbuvir is assigned for management of Zika virus infection, doubled dosage of the present dosage for hepatitis C management is recommended.
Related Concept Videos
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Dosage Regimen: Multiple Oral Dosage
Subviral Agents
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

